EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieÄquivalenzstudie

Magnetic resonance imaging‐targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial

Yongbing Cheng, Haifeng Huang, Miao Wang, Liangyong Zhu, Shan Peng, Danyan Li, Giancarlo Marra, Ruowen Qi, Xuefei Ding, Ming Liu, Xuefeng Qiu, Hongqian Guo iD

Cancer · 2026

DOI: 10.1002/cncr.70493 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2026. Verfasst von Yongbing Cheng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Image-Guided Biopsy, Prostate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Medical Key Discipline Cultivation Unit, Sino-German Mobility Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Index lesion‐focused ipsilateral systematic biopsy (iSB) has been proposed as a core‐reduction alternative to MRI‐targeted biopsy combined with systematic biopsy (TB + SB) for prostate cancer, but prospective multicenter validation is limited.

Methods

This prospective multicenter trial (NCT06584279) enrolled biopsy‐naive men with Prostate Imaging Reporting and Data System (PI‐RADS) ≥4 lesions or PI‐RADS 3 plus prostate‐specific antigen (PSA) density ≥0.15 ng/mL/cm 3 . All underwent MRI‐targeted biopsy (≥2 cores/lesion) with 12‐core SB. Through core‐level reclassification, the authors simulated TB + iSB (targeted biopsy combined with index lesion‐ipsilateral systematic biopsy). The primary outcome was cancer detection rate (CDR) of clinically significant prostate cancer (csPCa; Grade Group ≥2) with a noninferiority margin of –3%. Secondary outcomes included clinically insignificant prostate cancer (cisPCa; Grade Group 1) detection and pathological concordance after radical prostatectomy.

Results

Among 564 men (median age, 69 years; median PSA, 7.3 ng/mL), TB + iSB demonstrated a noninferior csPCa CDR versus TB + SB (40.78% vs. 42.38%; difference, –1.6 percentage points; 95% CI, –2.69 to –0.50), with the lower bound above the –3% noninferiority margin. The cisPCa CDR was slightly lower with TB + iSB than with TB + SB (13.83% vs. 14.36%; difference, –0.53 percentage points; 95% CI, –2.01 to 0.92). Among 189 surgical patients, pathological concordance was similar, whereas upgrading was numerically more frequent and downgrading numerically less frequent under simulated TB + iSB.

Conclusions

TB + iSB met the prespecified noninferiority criterion for csPCa detection relative to TB + SB and may represent a promising core‐reduction strategy in transperineal MRI‐guided biopsy, although the full protocol still provided additional contralateral information.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMagnetic Resonance ImagingImage-Guided BiopsyProstateHumansMaleAgedMiddle AgedProspective StudiesProstate-Specific AntigenNeoplasm GradingClinical Relevance

Stichwörter der Autor:innen

biopsyipsilateral systematic biopsymagnetic resonance imagingnoninferiorityprostatic neoplasms

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Institute of Urology, Nanjing University, Nanjing, China.
  • Department of Urology, Beijing Hospital, National Center of Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of Me…
  • Department of Urology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
  • Department of Pathology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of Radiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

ORCID-Profile: Hongqian Guo

Förderung

  • National Natural Science Foundation of China
  • Jiangsu Provincial Medical Key Discipline Cultivation Unit
  • Sino-German Mobility Programme

Zitieren

APA

Cheng, Y., Huang, H., Wang, M., Zhu, L., Peng, S., Li, D., Marra, G., Qi, R., Ding, X., Liu, M., Qiu, X., & Guo, H. (2026). Magnetic resonance imaging‐targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial. Cancer. https://doi.org/10.1002/cncr.70493

Vancouver

Cheng Y, Huang H, Wang M, Zhu L, Peng S, Li D, et al. Magnetic resonance imaging‐targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial. Cancer. 2026. doi:10.1002/cncr.70493

BibTeX
@article{Cheng2026,
  author = {Cheng, Yongbing and Huang, Haifeng and Wang, Miao and Zhu, Liangyong and Peng, Shan and Li, Danyan and Marra, Giancarlo and Qi, Ruowen and Ding, Xuefei and Liu, Ming and Qiu, Xuefeng and Guo, Hongqian},
  title = {Magnetic resonance imaging‐targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70493}
}
Kostenlos starten →